- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05874180
A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition
May 16, 2023 updated by: Dong Wha Pharmaceutical Co. Ltd.
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of DW6013 and Loose Combination of Each Component in Healthy Adult Volunteers in Fed Condition
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fed condition.
Study Overview
Detailed Description
This is a Phase 1, randomized, open-label, Oral, Single-dose, two-way crossover study in healthy subjects
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cheongju-si, Korea, Republic of
- Chungbuk National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy subjects aged up to 19 years
- Subjects weighing at least 50.0 kg and no more than 100 kg (inclusive) with a BMI between 18.5 kg/m2 and 30.0 kg/m2
- Subjects with neither congenital nor chronic diseases requiring treatment, and no abnormal symptoms or findings upon medical examination
- Subjects considered eligible for the study participation in accordance to the results of clinical laboratory tests, vital signs, physical examinations and 12-lead ECG conducted at the time of screening, based on the investigational product (IP) characteristics
- Subjects who has a full understanding in participation of the study, voluntarily provide a written consent in participation, and give full agreement in following the subject guidelines throughout the entire study period
Exclusion Criteria:
- Subjects with any clinically significant hepatic, renal, nervous, respiratory, endocrine, circulatory, tumor, genitourinary, cardiovascular, digestive, musculoskeletal systemic diseases or other medical history
- Pregnant subjects with a positive urine HCG test, or lactating female subjects
- Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration
- Subjects with clinically significant 12-lead ECG findings at the time of screening
- Subjects with a past history of drug abuse or a positive urine drug test
- Subjects with SBP ≥ 150 mmHg or ≤ 90 mmHg; DBP ≥ 100 mmHg or ≤ 60 mmHg; PR ≤ 40 bpm or ≥ 100 bpm at the time of screening
- Subjects following an unusual diet or consumption of food which may affect the absorption, distribution, metabolism and excretion of the IP
- Subjects who have administered any prescription drugs or herbal medicines that may affect the characteristics of clinical investigational drugs within 2 weeks prior to the first administration date, or have administered any over-the-counter (OTC) or vitamin preparations within 10 days
- Subjects who have participated and were given any other study drugs in other clinical study within 6 months prior to the first IP administration
- Subjects who have consistently drunk alcohol within 6 months
- Subjects who have smoked more than 10 cigarettes/day on average
- Subjects who have eaten or cannot refrain from eating grapefruit (grapefruit)-containing food from 48 hours before the first administration until the time of PSV
- Subjects who have consumed or cannot refrain from consuming caffeine-containing food during the period from 24 hours prior to administration of each period to the time of the last blood sampling
- Subjects who have done and are unable to refrain from strenuous activity
- Subjects who are planning for pregnancy or not willing to use a medically reliable forms of contraception
- Subjects otherwise considered ineligible for participation due to other reasons including clinical laboratory test results not mentioned in the inclusion/exclusion criteria at the investigator's discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence A
Period 1: Linagliptin and Metformin / Period 2: DW6013
|
Drug: DW6013 Single oral administration of DW6013 in fed condition Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Other Names:
|
Experimental: Sequence B
Period 1: DW6013 / Period 2: Linagliptin and Metformin
|
Drug: DW6013 Single oral administration of DW6013 in fed condition Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t
Time Frame: up to 48 hours
|
AUC0-t of Metformin
|
up to 48 hours
|
Cmax
Time Frame: up to 48 hours
|
Cmax of Metformin
|
up to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: up to 48 hours
|
Tmax of Metformin
|
up to 48 hours
|
AUCinf
Time Frame: up to 48 hours
|
AUCinf of Metformin
|
up to 48 hours
|
t1/2
Time Frame: up to 48 hours
|
t1/2 of Metformin
|
up to 48 hours
|
CL/F
Time Frame: up to 48 hours
|
CL/F of Metformin
|
up to 48 hours
|
Vd/F
Time Frame: up to 48 hours
|
Vd/F of Metformin
|
up to 48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2023
Primary Completion (Actual)
February 1, 2023
Study Completion (Actual)
February 3, 2023
Study Registration Dates
First Submitted
April 6, 2023
First Submitted That Met QC Criteria
May 16, 2023
First Posted (Actual)
May 24, 2023
Study Record Updates
Last Update Posted (Actual)
May 24, 2023
Last Update Submitted That Met QC Criteria
May 16, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DW6013-I-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on DW6013
-
Dong Wha Pharmaceutical Co. Ltd.CompletedHealthy SubjectsKorea, Republic of